These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 26488675

  • 1. Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics.
    Hwang TJ, Lo WM, Chan HY, Lin CF, Hsieh MH, Liu CC, Liu CM, Hwu HG, Kuo CH, Chen WJ.
    J Clin Psychopharmacol; 2015 Dec; 35(6):635-44. PubMed ID: 26488675
    [Abstract] [Full Text] [Related]

  • 2. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
    Kim CY, Chung S, Lee JN, Kwon JS, Kim DH, Kim CE, Jeong B, Jeon YW, Lee MS, Jun TY, Jung HY.
    Int Clin Psychopharmacol; 2009 Jul; 24(4):181-8. PubMed ID: 19451828
    [Abstract] [Full Text] [Related]

  • 3. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering.
    Takeuchi H, Suzuki T, Uchida H, Nakajima S, Nomura K, Kikuchi T, Manki H, Watanabe K, Kashima H.
    J Clin Psychopharmacol; 2008 Oct; 28(5):540-3. PubMed ID: 18794650
    [Abstract] [Full Text] [Related]

  • 4. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil.
    Risinger R, Hard M, Weiden PJ.
    Psychopharmacol Bull; 2017 Aug 01; 47(3):26-34. PubMed ID: 28839337
    [Abstract] [Full Text] [Related]

  • 5. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E, Tourjman V.
    Clin Ther; 2010 Aug 01; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [Abstract] [Full Text] [Related]

  • 6. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR.
    Arch Gen Psychiatry; 2003 Jul 01; 60(7):681-90. PubMed ID: 12860772
    [Abstract] [Full Text] [Related]

  • 7. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.
    Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, Ingenito GG, Aripiprazole Study Group.
    Psychopharmacology (Berl); 2003 Apr 01; 166(4):391-9. PubMed ID: 12610718
    [Abstract] [Full Text] [Related]

  • 8. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study.
    Correll CU, Kohegyi E, Zhao C, Baker RA, McQuade R, Salzman PM, Sanchez R, Nyilas M, Carson W.
    J Am Acad Child Adolesc Psychiatry; 2017 Sep 01; 56(9):784-792. PubMed ID: 28838583
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.
    Hard ML, Mills RJ, Sadler BM, Wehr AY, Weiden PJ, von Moltke L.
    CNS Drugs; 2017 Jul 01; 31(7):617-624. PubMed ID: 28597226
    [Abstract] [Full Text] [Related]

  • 10. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
    Kwon JS, Jang JH, Kang DH, Yoo SY, Kim YK, Cho SJ, APLUS study group.
    Psychiatry Clin Neurosci; 2009 Feb 01; 63(1):73-81. PubMed ID: 19154213
    [Abstract] [Full Text] [Related]

  • 11. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC, González Sánchez L, García Resa E, Bonete Llácer JM, Román Rodríguez A, Pecino Esquerdo B, Pérez Martínez E.
    Int J Psychiatry Clin Pract; 2020 Mar 01; 24(1):10-17. PubMed ID: 31933402
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
    Weiden PJ, Du Y, von Moltke L, Wehr A, Hard M, Marandi M, Walling DP.
    CNS Drugs; 2020 Sep 01; 34(9):961-972. PubMed ID: 32621071
    [Abstract] [Full Text] [Related]

  • 13. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID, Mankoski R, Eudicone JM, Marcus RN, Tran QV, Assunção-Talbott S.
    J Affect Disord; 2009 May 01; 115(1-2):18-26. PubMed ID: 19230981
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
    Kim SW, Shin IS, Kim JM, Bae KY, Yang SJ, Yoon JS.
    Clin Neuropharmacol; 2010 May 01; 33(3):121-5. PubMed ID: 20502130
    [Abstract] [Full Text] [Related]

  • 15. Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores.
    Ismail Z, Peters-Strickland T, Miguelez M, Baker RA, Hertel P, Eramo A, Jin N, Perry P, Sanchez R, McQuade RD, Kane JM.
    J Clin Psychopharmacol; 2017 Jun 01; 37(3):347-350. PubMed ID: 28383362
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
    Zhao T, Park TW, Yang JC, Huang GB, Kim MG, Lee KH, Chung YC.
    Int Clin Psychopharmacol; 2012 Jul 01; 27(4):184-90. PubMed ID: 22426471
    [Abstract] [Full Text] [Related]

  • 17. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP, Daniel DG, Carson WH, McQuade RD, Marcus RN.
    J Psychiatr Res; 2007 Dec 01; 41(11):895-905. PubMed ID: 17631314
    [Abstract] [Full Text] [Related]

  • 18. Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period.
    Weiden PJ, Du Y, Liu CC, Stanford AD.
    CNS Spectr; 2019 Aug 01; 24(4):419-425. PubMed ID: 29941057
    [Abstract] [Full Text] [Related]

  • 19. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML, Shen WW, Chen CH.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec 12; 32(8):1978-81. PubMed ID: 18848860
    [Abstract] [Full Text] [Related]

  • 20. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.
    Ryckmans V, Kahn JP, Modell S, Werner C, McQuade RD, Kerselaers W, Lissens J, Sanchez R.
    Pharmacopsychiatry; 2009 May 12; 42(3):114-21. PubMed ID: 19452380
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.